Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Chang (Seoul, Republic of Korea), M. Shin (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea). Clinical characteristics of anti-Jo-1-positive interstitial lung disease. 5183

Member's Comments

No comment yet.

Related content which might interest you: Clinical characteristics of patients with unclassifiable interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia Source: International Congress 2017 – Lung function testing Year: 2017 Clinical features of interstitial lung disease in polymyositis and dermatomyositis Source: Eur Respir J 2006; 28: Suppl. 50, 828s Year: 2006 Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006 Clinical trials in interstitial lung disease Source: Eur Respir Mon; 2009: 46: 67–84 Year: 2009 Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies Source: International Congress 2016 – Connective tissue disorders Year: 2016 Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Clinical characteristics and prognosis of fibrotic nonspecific interstitial pneumonia Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Clinical use of interstitial lung disease guidelines Source: Eur Respir Mon; 2009: 46: 386–395 Year: 2009 Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Clinical profile of idiopathic pulmonary fibrosis with lung cancer Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Characterization of interstitial pneumonia associated with clinical amyopathic dermatomyositis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Prognostic relevance of histologic features in nonspecific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Clinical course and outcome of vasculitis related interstitial lung disease Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Clinical features and outcomes of patients with myositis associated-interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Are there any clinical differences between SSc-ILD and UCTD suspected of SSc -ILD? Source: International Congress 2015 – Connective tissue disorders Year: 2015